Cargando…
Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/ https://www.ncbi.nlm.nih.gov/pubmed/28941314 http://dx.doi.org/10.1111/dom.13120 |
_version_ | 1783304031575212032 |
---|---|
author | Hjerpsted, Julie B. Flint, Anne Brooks, Ashley Axelsen, Mads B. Kvist, Trine Blundell, John |
author_facet | Hjerpsted, Julie B. Flint, Anne Brooks, Ashley Axelsen, Mads B. Kvist, Trine Blundell, John |
author_sort | Hjerpsted, Julie B. |
collection | PubMed |
description | AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous semaglutide, dose‐escalated to 1.0 mg, or placebo. After each 12‐week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed. RESULTS: Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC(0‐5h)]; estimated treatment difference: glucose −1.34 mmol h/L [−2.42, −0.27]; insulin −921 pmol h/L [−1461, −381]; C‐peptide −1.42 nmol h/L [−2.33, −0.51]). Fasting and postprandial lipid metabolism improved with semaglutide vs placebo. First‐hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC(0‐1h); estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide‐treated subjects. Overall gastric emptying (AUC(0‐5h)) was not statistically different between treatments. Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively). CONCLUSION: Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first‐hour delay with semaglutide may contribute to a slower entry of glucose into the circulation. |
format | Online Article Text |
id | pubmed-5836914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58369142018-03-12 Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity Hjerpsted, Julie B. Flint, Anne Brooks, Ashley Axelsen, Mads B. Kvist, Trine Blundell, John Diabetes Obes Metab Original Articles AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous semaglutide, dose‐escalated to 1.0 mg, or placebo. After each 12‐week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed. RESULTS: Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC(0‐5h)]; estimated treatment difference: glucose −1.34 mmol h/L [−2.42, −0.27]; insulin −921 pmol h/L [−1461, −381]; C‐peptide −1.42 nmol h/L [−2.33, −0.51]). Fasting and postprandial lipid metabolism improved with semaglutide vs placebo. First‐hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC(0‐1h); estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide‐treated subjects. Overall gastric emptying (AUC(0‐5h)) was not statistically different between treatments. Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively). CONCLUSION: Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first‐hour delay with semaglutide may contribute to a slower entry of glucose into the circulation. Blackwell Publishing Ltd 2017-10-27 2018-03 /pmc/articles/PMC5836914/ /pubmed/28941314 http://dx.doi.org/10.1111/dom.13120 Text en © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Hjerpsted, Julie B. Flint, Anne Brooks, Ashley Axelsen, Mads B. Kvist, Trine Blundell, John Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title | Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title_full | Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title_fullStr | Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title_full_unstemmed | Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title_short | Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
title_sort | semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/ https://www.ncbi.nlm.nih.gov/pubmed/28941314 http://dx.doi.org/10.1111/dom.13120 |
work_keys_str_mv | AT hjerpstedjulieb semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity AT flintanne semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity AT brooksashley semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity AT axelsenmadsb semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity AT kvisttrine semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity AT blundelljohn semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity |